Mineralys Therapeutics Inc (MLYS) Q3 2025 Earnings Call Highlights: Strong Financial Position ... [Yahoo! Finance]
Mineralys Therapeutics, Inc. (MLYS)
Company Research
Source: Yahoo! Finance
R&D Expenses: $31.5 million for Q3 2025, down from $54 million for Q3 2024. G&A Expenses: $9.7 million for Q3 2025, up from $6.1 million for Q3 2024. Total Other Income, Net: $4.2 million for Q3 2025, compared to $3.8 million for Q3 2024. Net Loss: $36.9 million for Q3 2025, compared to $56.3 million for Q3 2024. Warning! GuruFocus has detected 2 Warning Signs with MLYS. Is MLYS fairly valued? Test your thesis with our free DCF calculator. Release Date: November 10, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points Mineralys Therapeutics Inc ( NASDAQ:MLYS ) received pre-NDA feedback from the FDA with no surprises, indicating a smooth path towards NDA submission. The company's clinical trials, Launch-HTN and Advance-HTN, demonstrated that lorundrostat offers a clinically meaningful and sustained reduction in systolic blood pressure. Lorundrostat showed consistent, statistically significant, an
Show less
Read more
Impact Snapshot
Event Time:
MLYS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MLYS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MLYS alerts
High impacting Mineralys Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MLYS
News
- Mineralys Therapeutics (MLYS) Files Lorundrostat NDA Following Positive Clinical Milestones [Yahoo! Finance]Yahoo! Finance
- Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026GlobeNewswire
- Is It Too Late To Consider Mineralys Therapeutics After Its Huge 2025 Share Price Surge [Yahoo! Finance]Yahoo! Finance
- 4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow [Yahoo! Finance]Yahoo! Finance
- Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears [Yahoo! Finance]Yahoo! Finance
MLYS
Earnings
- 11/10/25 - Beat
MLYS
Sec Filings
- 2/9/26 - Form 144
- 2/5/26 - Form SCHEDULE
- 1/21/26 - Form SCHEDULE
- MLYS's page on the SEC website